Sentence examples for poor accessibility of from inspiring English sources
For the narrow spacing, the enhancement in capacitance is not so obvious, which could be ascribed to the poor accessibility of the interlayer by electrolyte ions.
It may be deduced that its poor catalytic activity at low temperature is due to poor accessibility of MAO to chloride and, hence, less alkylation.
Some stakeholders have also mentioned failings related to the deterioration of monitoring networks, inadequate communication of warnings by forecasters to end users, and poor accessibility of warning systems.
The high interactive effect of N and P on P uptake is an indication of the relatively poor accessibility of soil P which improved with greater soils exploitation due to better root growth.
Application to heavy oil, despite its higher sulfur content, is unpractical, due to the poor accessibility of large molecules in the narrow pores and steric hindrance that reduces adsorption effectiveness.
These observations, further explored by means of molecular modeling, reveal the previously unrecognized unpredictability of the benefits of multivalency, possibly because of poor accessibility of the viral targets to polymeric agents.
In addition, 32.7% of the participants complained of poor accessibility to city hospitals; 25.3% of the participants had poor accessibility to county hospitals; and17.9% of the participants had poor accessibility to township and village hospitals.
That study assumed employed persons to have a more restricted time budget and poorer accessibility of health care facilities.
Because of poor accessibility to the remote area of the outbreak and thunderstorms, a field investigation on the plague focus was not started until April 1, which was 2 months after the outbreak (Table 3).
In urban areas, the hospital was the place of choice while in rural areas, majority of women preferred to deliver at home either because of poverty or because of poor accessibility to health care services.
The radiopharmaceutical 111In capromab pendetide (ProstaScint, EUSA Pharma, licenced in the USA since 1997) is a monoclonal antibody (mAb) that targets an internal epitope of PSMA, which limits its utility because of poor accessibility to circulating mAb [5].
